Drugs / CEA peptide 1-6D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00057915 | Sep 2003 → Aug 2006 | cancer of unknown primary site | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEA peptide 1-6D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057915 ↗ |
| Route | Subcutaneous | “CAP 1-6D-pulsed DC and CMV pp65 peptide-pulsed DC subcutaneously and intradermally” NCT00057915 ↗ |